Exosens (EXENS) AI Stock Analysis

• Market Cap: €2.42B
• Dividend Yield: 0.21%
• Average Volume (3M): 187.72K
• Price to Earnings (P/E): 43.4
• Beta (1Y): 0.64
• Revenue Growth: 22.05%
• EPS Growth: 2658.04%
• Country: FR
• Employees: 1,214
• Sector: General
• Sector Strength: N/A
• Industry: Hardware, Equipment & Parts
• EPS (TTM): 0.55
• Shares Outstanding: 50,782,550
• 10 Day Avg. Volume: 184,892
• 30 Day Avg. Volume: 187,724
• PEG Ratio: 4.50
• Price to Book (P/B): 2.39
• Price to Sales (P/S): 2.50
• P/FCF Ratio: 10.26
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €48.25
• Price Target Upside: 1.26% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 4
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 74 Outperform
• Price Target: €54.00 ▲(13.33% Upside)

Exosens demonstrates strong financial performance with robust revenue and profitability growth, supported by a solid balance sheet and excellent cash flow management. The technical analysis indicates a positive market trend, although the high P/E ratio suggests potential overvaluation. The absence of earnings call and corporate events data limits further insights.

Positive Factors

Revenue Growth

Sustained revenue growth indicates successful market expansion and product adoption, enhancing long-term business prospects.

Cash Flow Management

Strong cash flow management ensures liquidity and operational flexibility, supporting future investments and stability.

Profitability

Improved profitability margins indicate effective cost management and pricing strategies, contributing to long-term financial health.

Negative Factors

High Growth Risks

Rapid growth can strain resources and lead to operational challenges, potentially impacting long-term sustainability if not managed well.

Historical Leverage

Past leverage levels could pose risks if growth slows, as debt obligations may limit financial flexibility and increase vulnerability.

Valuation Concerns

Perceived overvaluation may lead to investor caution, affecting stock performance and capital raising ability if market conditions change.

Exosens Business Overview & Revenue Model

Company Description

Exosens (EXENS) is a technology company specializing in advanced sensory solutions and smart devices, primarily operating in the consumer electronics and healthcare sectors. The company focuses on developing innovative products that enhance user experience through sensory technology, including wearable devices, smart home systems, and health monitoring solutions. Exosens aims to integrate cutting-edge technology with everyday living, providing users with enhanced connectivity, health insights, and improved quality of life.

How the Company Makes Money

Exosens generates revenue through multiple channels, including direct sales of its consumer electronics and smart devices, subscription services for health monitoring and data analytics, and partnerships with healthcare providers and technology firms. Key revenue streams include the sale of wearable technology that tracks health metrics, licensing fees from proprietary technology used in third-party products, and recurring revenue from subscriptions to software platforms that analyze user data for health and wellness insights. Additionally, collaborations with industry partners in the healthcare sector bolster its earnings by expanding market reach and integrating Exosens products into broader health management solutions.

Exosens Financial Statement Overview

Summary

Exosens has shown remarkable improvement across its financial statements, with strong revenue and profitability growth, a solid balance sheet with significantly reduced debt, and excellent cash flow generation. The company appears to be on a solid trajectory, though attention should be paid to maintaining momentum and managing potential risks associated with high growth rates and historical leverage.

Income Statement

Exosens demonstrated strong revenue growth with a 23.58% increase in 2024 over 2023. The company's gross profit margin improved to 57.23%, indicating efficient production and sales strategies. Net profit margin has also increased to 7.79%, reflecting enhanced profitability. The EBIT and EBITDA margins are robust at 19.51% and 29.23% respectively, highlighting effective operational management.

Balance Sheet

Exosens has significantly improved its financial position, reducing total debt drastically and increasing stockholders' equity, resulting in a healthier debt-to-equity ratio of 0.03. The equity ratio of 50.50% suggests a strong asset base relative to liabilities, although the high growth and leverage in previous years indicate potential risks.

Cash Flow

The company shows impressive cash flow management with a substantial increase in free cash flow and operating cash flow. The operating cash flow to net income ratio is strong at 3.13, indicating good cash generation relative to net earnings. The free cash flow to net income ratio is excellent, showcasing the company's ability to generate cash from its operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	431.73M	394.10M	318.80M	200.75M	166.17M	149.86M
Gross Profit	186.15M	225.60M	176.81M	113.95M	100.03M	91.83M
EBITDA	102.80M	115.20M	83.91M	51.25M	-101.18M	36.51M
Net Income	55.74M	30.70M	17.14M	11.21M	-148.97M	-15.83M
Balance Sheet
Total Assets	867.32M	817.00M	656.41M	529.25M	460.52M	598.10M
Cash, Cash Equivalents and Short-Term Investments	89.78M	150.20M	15.53M	29.00M	15.93M	31.74M
Total Debt	268.44M	10.90M	311.77M	255.28M	208.11M	451.59M
Total Liabilities	437.82M	404.40M	452.35M	346.20M	288.41M	501.00M
Stockholders Equity	429.50M	412.60M	204.06M	183.05M	172.11M	97.10M
Cash Flow
Free Cash Flow	47.84M	96.20M	19.53M	25.69M	23.07M	30.35M
Operating Cash Flow	91.90M	96.20M	50.46M	47.48M	42.66M	44.12M
Investing Cash Flow	-110.77M	-72.70M	-99.64M	-55.48M	-21.26M	-13.77M
Financing Cash Flow	-9.00M	76.30M	35.49M	20.26M	-36.83M	-5.01M

Exosens Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 47.65
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:EXENS, the sentiment is Positive. The current price of 47.65 is above the 20-day moving average (MA) of 47.40, above the 50-day MA of 44.26, and above the 200-day MA of 37.76, indicating a bullish trend. The MACD of 0.82 indicates Positive momentum. The RSI at 54.38 is Neutral, neither overbought nor oversold. The STOCH value of 21.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:EXENS.

Exosens Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
EXENS	74 Outperform	€2.42B	43.41	―	0.21%	22.05%	2658.04%
PLNW	67 Neutral	€1.43B	29.37	―	1.59%	13.17%	22.60%
ALICA	60 Neutral	€52.41M	13.87	―	2.05%	14.84%	15.82%
Sector *	55 Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
LACR	55 Neutral	€55.25M	-1.38	-4.96%	6.86%	-29.10%	-173.56%